In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Tries to Buy Time

Executive Summary

Facing a steep patent cliff and a dearth of late-stage drugs, Lilly is slashing expenses, reorganizing R&D, and hoping to attract investors to share the risks and rewards of pipeline development. Will these moves be enough?

Related Content

Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Lilly To Cease Development Of Alzheimer's Drug
Flexion Exploits Big Pharma as Discovery Supplier
Biopharma Trends: Nowhere To Go But Up
GSK's Virtual-Proof-of-Concept Unit in Tune with Lilly's Chorus
Merck Buys Schering-Plough -- and Time
Pfizer/Wyeth: Industrializing Pharma?
Alzheimer's Development Financing: Risky Therapies Call for Innovative Deals
Lilly and Merck Lead the Way With Asian FIPNet Strategies
Lilly's Chorus Experiment


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts